Blurbs

Analysts’ Top Healthcare Picks: Rockwell Med (RMTI), Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTIResearch Report) and Biogen (BIIBResearch Report) with bullish sentiments.

Rockwell Med (RMTI)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $3.00. The company’s shares closed last Friday at $0.47, close to its 52-week low of $0.34.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -24.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Rockwell Med has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.

See today’s best-performing stocks on TipRanks >>

Biogen (BIIB)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Biogen, with a price target of $270.00. The company’s shares closed last Friday at $239.30, close to its 52-week low of $217.10.

According to TipRanks.com, Fein is a 3-star analyst with an average return of 1.6% and a 38.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $290.00, a 23.4% upside from current levels. In a report issued on January 7, Truist Financial also maintained a Buy rating on the stock with a $343.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RMTI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed